Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:food:aim_health:aging [03.13.2019]
sallieq [with additional studies]
home:food:aim_health:aging [04.20.2019] (current)
sallieq [with additional studies]
Line 22: Line 22:
 Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed>​long: ​   20079903}})) ​ Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed>​long: ​   20079903}})) ​
  
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) +Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) (({{pubmed>​long: ​   20074257}}))
  
 Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pubmed>​long:​24379062}})) ​ Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pubmed>​long:​24379062}})) ​
home/food/aim_health/aging.txt · Last modified: 04.20.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.